Elisa Ignatius is an Infectious Disease physician affiliated with Johns Hopkins University. OpenAlex indexes 28 publications with 536 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1717 E Monument St
Baltimore, MD 212870027
Telephone
410-614-5611Registry record last updated 8 Nov 2018.
Clinical trials
- A Study of Standard Drugs for Mycobacterium Avium Complex
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
89.2%Aminoglycoside Antibacterial23.1%Arikayce77%Amikacin Sulfate23%Part D<11 patientsAntimycobacterial18.1%Ethambutol Hcl100%Part D≥14 patients+ 5 more classes in this area
Respiratory
10.8%beta2-Adrenergic Agonist10.8%Albuterol Sulfate Hfa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Optimizing Anti-mycobacterial Therapy Using A Pharmacology-based Approach
Johns Hopkins University
FY2026$198,720K23AI159145 - Optimizing Anti-mycobacterial Therapy Using A Pharmacology-based Approach
Johns Hopkins University
FY2025$198,720K23AI159145 - Optimizing Anti-mycobacterial Therapy Using A Pharmacology-based Approach
Johns Hopkins University
FY2024$198,720K23AI159145
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Aspergillus SP. Positive Airway Samples in People With Non-CF Bronchiectasis is Associated With Higher Biomarkers of Systemic TH2 Inflammation, Allergic Airway Disease, and Airway Co-infection
American Journal of Respiratory and Critical Care Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”